FR17C1019I2 - Compose tetracyclique - Google Patents
Compose tetracycliqueInfo
- Publication number
- FR17C1019I2 FR17C1019I2 FR17C1019C FR17C1019C FR17C1019I2 FR 17C1019 I2 FR17C1019 I2 FR 17C1019I2 FR 17C1019 C FR17C1019 C FR 17C1019C FR 17C1019 C FR17C1019 C FR 17C1019C FR 17C1019 I2 FR17C1019 I2 FR 17C1019I2
- Authority
- FR
- France
- Prior art keywords
- tetracyclic compound
- tetracyclic
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009139691 | 2009-06-10 | ||
PCT/JP2010/059785 WO2010143664A1 (ja) | 2009-06-10 | 2010-06-09 | 4環性化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR17C1019I1 FR17C1019I1 (ru) | 2017-07-21 |
FR17C1019I2 true FR17C1019I2 (fr) | 2018-04-27 |
Family
ID=43308919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR17C1019C Active FR17C1019I2 (fr) | 2009-06-10 | 2017-06-01 | Compose tetracyclique |
Country Status (40)
Country | Link |
---|---|
US (6) | US9126931B2 (ru) |
EP (4) | EP2441753B1 (ru) |
JP (2) | JP4588121B1 (ru) |
KR (1) | KR101351120B1 (ru) |
CN (1) | CN102459172B (ru) |
AR (1) | AR077025A1 (ru) |
AU (1) | AU2010259588B2 (ru) |
BR (1) | BRPI1011649B1 (ru) |
CA (1) | CA2764653C (ru) |
CL (1) | CL2011002433A1 (ru) |
CO (1) | CO6430460A2 (ru) |
CR (1) | CR20110492A (ru) |
CY (2) | CY1117752T1 (ru) |
DK (3) | DK2975024T3 (ru) |
EC (1) | ECSP12011573A (ru) |
ES (3) | ES2575084T3 (ru) |
FR (1) | FR17C1019I2 (ru) |
HK (1) | HK1165794A1 (ru) |
HR (3) | HRP20160605T1 (ru) |
HU (4) | HUE046402T2 (ru) |
IL (1) | IL216817A (ru) |
LT (3) | LT3345903T (ru) |
LU (1) | LUC00022I2 (ru) |
MA (1) | MA33418B1 (ru) |
MX (1) | MX2011013306A (ru) |
MY (1) | MY159850A (ru) |
NL (1) | NL300876I2 (ru) |
NO (2) | NO2975024T3 (ru) |
NZ (1) | NZ597477A (ru) |
PE (1) | PE20121065A1 (ru) |
PL (3) | PL2441753T3 (ru) |
PT (3) | PT2441753E (ru) |
RS (1) | RS58855B1 (ru) |
RU (2) | RU2725140C2 (ru) |
SG (1) | SG175707A1 (ru) |
SI (3) | SI2441753T1 (ru) |
TW (2) | TWI531367B (ru) |
UA (1) | UA107796C2 (ru) |
WO (1) | WO2010143664A1 (ru) |
ZA (1) | ZA201106938B (ru) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3345903T (lt) * | 2009-06-10 | 2019-12-10 | Chugai Pharmaceutical Co Ltd | Tetracikliniai junginiai |
CA2808210C (en) * | 2010-08-20 | 2019-10-01 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds having alk inhibitory activity and compositions thereof |
JP5006987B2 (ja) * | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | 4環性化合物を含む医薬 |
EP3815685A3 (en) * | 2011-10-31 | 2021-10-13 | The Methodist Hospital Research Institute | Compound comprising a mao targeting/seeker moiety for treating human gliomas |
CN106166155B (zh) | 2012-03-06 | 2019-01-18 | 赛福伦公司 | 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物 |
LT2902029T (lt) * | 2012-09-25 | 2018-10-25 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitorius |
EP2935251A1 (en) * | 2012-12-20 | 2015-10-28 | Concert Pharmaceuticals Inc. | Deuterated alk inhibitors |
WO2014121654A1 (zh) * | 2013-02-05 | 2014-08-14 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
JP6495238B2 (ja) * | 2013-04-02 | 2019-04-03 | トピバート ファーマ リミテッド | キナーゼ阻害剤として有用な尿素誘導体 |
CN104109168B (zh) * | 2013-04-20 | 2017-02-15 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
CN104130241A (zh) * | 2013-05-05 | 2014-11-05 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
CN104177332A (zh) * | 2013-05-20 | 2014-12-03 | 中国科学院上海药物研究所 | 酰胺基取代的吲哚并萘酮衍生物及其医药用途 |
CN104177342B (zh) * | 2013-05-21 | 2018-01-05 | 中国科学院上海药物研究所 | 杂环基取代的吲哚并萘酮衍生物及其医药用途 |
CN105579459B (zh) * | 2013-06-01 | 2018-03-13 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
CN104230960B (zh) * | 2013-06-06 | 2017-02-15 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
CN105338980A (zh) | 2013-06-18 | 2016-02-17 | 诺华股份有限公司 | 药物组合 |
CN104804016B (zh) * | 2014-01-23 | 2017-06-20 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
CA2946268A1 (en) * | 2014-04-25 | 2015-10-29 | Chugai Seiyaku Kabushiki Kaisha | Crystal of tetracyclic compound |
CA3140565C (en) | 2014-04-25 | 2022-10-11 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
CA2942186C (en) * | 2014-06-18 | 2023-06-27 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising non-ionic surfactants |
TWI765410B (zh) * | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | 4環性化合物的非晶質體的用途 |
KR101909404B1 (ko) | 2014-09-29 | 2018-10-17 | 수안주 파마 코포레이션 리미티드 | 역형성 림프종 키나제의 폴리사이클릭 저해제 |
CN105566307B (zh) * | 2014-10-11 | 2019-04-23 | 中国科学院上海药物研究所 | 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途 |
CN104402862B (zh) | 2014-11-12 | 2016-10-05 | 苏州明锐医药科技有限公司 | 艾立替尼的制备方法 |
MX2017009246A (es) | 2015-01-16 | 2017-10-12 | Chugai Pharmaceutical Co Ltd | Farmaco de combinacion. |
US9573932B2 (en) * | 2015-03-02 | 2017-02-21 | Yong Xu | Synthesis of intermediates in the preparation of ALK inhibitor |
EP3268346B1 (en) * | 2015-03-11 | 2021-05-05 | International Flavors & Fragrances Inc. | Processes for the preparation of unsaturated malonates |
WO2016169504A1 (zh) | 2015-04-24 | 2016-10-27 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
WO2017053657A1 (en) | 2015-09-23 | 2017-03-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of alk and srpk and methods of use |
CN105777710B (zh) * | 2016-04-05 | 2018-09-04 | 湖南欧亚药业有限公司 | 一种艾乐替尼的合成方法 |
CN106946650B (zh) * | 2017-03-01 | 2021-06-08 | 南京远淑医药科技有限公司 | 一种盐酸阿雷替尼中间体的合成方法 |
CN106928185B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
CN107033125B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
CN106995433A (zh) * | 2017-04-21 | 2017-08-01 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼的制备方法 |
CN107033124B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
CN107129488A (zh) * | 2017-04-21 | 2017-09-05 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼的制备方法 |
CN106928125A (zh) * | 2017-04-21 | 2017-07-07 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼中间体的制备方法 |
CN106892860B (zh) * | 2017-04-21 | 2019-08-02 | 湖南博奥德药业有限公司 | 一种艾乐替尼中间体的制备方法 |
CN106928184B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
US20210084900A1 (en) | 2017-05-04 | 2021-03-25 | Basf Se | Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for Combating Phytopathogenic Fungi |
EP3649116A1 (en) * | 2017-07-05 | 2020-05-13 | Fresenius Kabi Oncology Limited | A process for preparing alectinib or a pharmaceutically acceptable salt thereof |
JP7054134B2 (ja) * | 2017-12-07 | 2022-04-13 | 国立大学法人京都大学 | ベンゾ[b]カルバゾール化合物及びそれを用いたイメージング |
CN109912655B (zh) * | 2017-12-13 | 2021-12-10 | 上海科技大学 | Alk蛋白降解剂及其抗肿瘤应用 |
CN108178743A (zh) * | 2018-02-08 | 2018-06-19 | 安庆奇创药业有限公司 | 一种艾乐替尼关键中间体的制备方法 |
KR102548191B1 (ko) * | 2018-04-09 | 2023-06-28 | 상하이테크 유니버시티 | 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용 |
WO2019211868A1 (en) * | 2018-04-30 | 2019-11-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile hydrochloride |
JP7346403B2 (ja) | 2018-06-29 | 2023-09-19 | 中外製薬株式会社 | 難溶性の塩基性薬剤を含有する医薬組成物 |
MX2021002311A (es) | 2018-09-04 | 2021-04-28 | Chugai Pharmaceutical Co Ltd | Metodo para producir un compuesto tetraciclico. |
WO2020069106A1 (en) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degraders that target alk and therapeutic uses thereof |
CN109438218B (zh) * | 2018-10-23 | 2021-04-09 | 成都艾必克医药科技有限公司 | 一种盐酸艾乐替尼中间体2-(4-乙基-3-碘苯基)-2-甲基丙酸的合成方法 |
CN109384664B (zh) * | 2018-11-20 | 2021-04-13 | 成都正善达生物医药科技有限公司 | 一种艾乐替尼中间体的制备方法 |
EP3556754A1 (en) * | 2018-12-07 | 2019-10-23 | Fresenius Kabi iPSUM S.r.l. | Process for the preparation of alectinib |
SG11202106635WA (en) | 2018-12-21 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and kinase inhibitor |
CN111349012B (zh) * | 2018-12-21 | 2023-01-10 | 上海复星星泰医药科技有限公司 | 一种卤代芳烃类化合物的制备方法及其中间体 |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN110590739A (zh) * | 2019-09-20 | 2019-12-20 | 中国药科大学 | 一种艾乐替尼的制备方法 |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AU2022215105A1 (en) | 2021-01-29 | 2023-07-20 | Chugai Seiyaku Kabushiki Kaisha | Drug composition for treating pediatric cancers |
EP4320153A1 (en) | 2021-04-09 | 2024-02-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
CN115340523B (zh) * | 2021-05-12 | 2023-12-15 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种具有alk抑制活性的化合物及其制备方法和用途 |
WO2023074785A1 (ja) | 2021-10-28 | 2023-05-04 | 中外製薬株式会社 | シロップ剤 |
WO2023161233A1 (en) * | 2022-02-22 | 2023-08-31 | Synthon B.V. | Solid forms of alectinib and alectinib salts |
CN115677659B (zh) * | 2022-10-11 | 2024-03-22 | 枣庄市润安制药新材料有限公司 | 一种阿雷替尼的制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0892090A (ja) * | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
EP0695755B1 (en) | 1994-08-04 | 1998-10-21 | F. Hoffmann-La Roche AG | Pyrrolocarbazole |
JPH08291285A (ja) * | 1995-04-21 | 1996-11-05 | Fuji Photo Film Co Ltd | 感光性組成物及びそれを用いた要素 |
EA001450B1 (ru) * | 1996-05-01 | 2001-04-23 | Эли Лилли Энд Компани | Галогензамещенные ингибиторы протеинкиназы с |
DE60033649D1 (de) * | 1999-05-14 | 2007-04-12 | Australian Nat University Acto | Verbindungen und therapeutische methoden |
CN100398519C (zh) * | 2003-02-28 | 2008-07-02 | 伊诺泰克制药公司 | 四环苯甲酰胺衍生物及其用法 |
EP1454992B1 (en) * | 2003-03-07 | 2006-05-31 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Anaplastic lymphoma kinase assay, reagents and compositions thereof |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7872014B2 (en) | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
US7378414B2 (en) * | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
US20080262021A1 (en) | 2003-11-21 | 2008-10-23 | Novartis Ag | 1H-Imidazoquinoline Derivatives as Prote In Kinase Inhibitors |
WO2005056529A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
TW200609215A (en) | 2004-03-19 | 2006-03-16 | Speedel Experimenta Ag | Organic compounds |
EP1730128A1 (en) * | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
EA013678B1 (ru) * | 2004-08-26 | 2010-06-30 | Пфайзер Инк. | Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы |
GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
JP2009514974A (ja) * | 2005-11-07 | 2009-04-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Pparモジュレーターとしての化合物および組成物 |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
ES2633318T3 (es) * | 2006-10-23 | 2017-09-20 | Cephalon, Inc. | Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met |
US8546394B2 (en) | 2007-04-17 | 2013-10-01 | Bristol-Myers Squibb Company | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors |
TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
PL2176231T3 (pl) | 2007-07-20 | 2017-04-28 | Nerviano Medical Sciences S.R.L. | Podstawione pochodne indazolu aktywne jako inhibitory kinazy |
CN101932325B (zh) * | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
CN102574830A (zh) | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 取代的1-氰基乙基杂环基甲酰胺化合物750 |
LT3345903T (lt) * | 2009-06-10 | 2019-12-10 | Chugai Pharmaceutical Co Ltd | Tetracikliniai junginiai |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
CA2808210C (en) * | 2010-08-20 | 2019-10-01 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds having alk inhibitory activity and compositions thereof |
LT2902029T (lt) * | 2012-09-25 | 2018-10-25 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitorius |
CA2946268A1 (en) * | 2014-04-25 | 2015-10-29 | Chugai Seiyaku Kabushiki Kaisha | Crystal of tetracyclic compound |
CA3140565C (en) * | 2014-04-25 | 2022-10-11 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
CA2942186C (en) * | 2014-06-18 | 2023-06-27 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising non-ionic surfactants |
TWI765410B (zh) * | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | 4環性化合物的非晶質體的用途 |
-
2010
- 2010-06-09 LT LT18158255T patent/LT3345903T/lt unknown
- 2010-06-09 SI SI201031199A patent/SI2441753T1/sl unknown
- 2010-06-09 KR KR1020117031143A patent/KR101351120B1/ko active Protection Beyond IP Right Term
- 2010-06-09 JP JP2010526082A patent/JP4588121B1/ja active Active
- 2010-06-09 SI SI201031961T patent/SI3345903T1/sl unknown
- 2010-06-09 SG SG2011072295A patent/SG175707A1/en unknown
- 2010-06-09 WO PCT/JP2010/059785 patent/WO2010143664A1/ja active Application Filing
- 2010-06-09 TW TW099118688A patent/TWI531367B/zh active
- 2010-06-09 HU HUE18158255A patent/HUE046402T2/hu unknown
- 2010-06-09 RU RU2015156881A patent/RU2725140C2/ru active
- 2010-06-09 AU AU2010259588A patent/AU2010259588B2/en active Active
- 2010-06-09 PT PT107861957T patent/PT2441753E/pt unknown
- 2010-06-09 EP EP10786195.7A patent/EP2441753B1/en active Active
- 2010-06-09 NZ NZ597477A patent/NZ597477A/en unknown
- 2010-06-09 NO NO15180863A patent/NO2975024T3/no unknown
- 2010-06-09 EP EP18158255.2A patent/EP3345903B1/en active Active
- 2010-06-09 AR ARP100102015A patent/AR077025A1/es active IP Right Grant
- 2010-06-09 CN CN201080025574.4A patent/CN102459172B/zh active Active
- 2010-06-09 TW TW105101212A patent/TWI624457B/zh active
- 2010-06-09 US US13/377,300 patent/US9126931B2/en active Active
- 2010-06-09 RS RS20110548A patent/RS58855B1/sr unknown
- 2010-06-09 PT PT151808631T patent/PT2975024T/pt unknown
- 2010-06-09 SI SI201031676T patent/SI2975024T1/en unknown
- 2010-06-09 LT LTEP15180863.1T patent/LT2975024T/lt unknown
- 2010-06-09 PE PE2011002060A patent/PE20121065A1/es active IP Right Grant
- 2010-06-09 BR BRPI1011649-4A patent/BRPI1011649B1/pt active IP Right Grant
- 2010-06-09 DK DK15180863.1T patent/DK2975024T3/en active
- 2010-06-09 PL PL10786195.7T patent/PL2441753T3/pl unknown
- 2010-06-09 HU HUE15180863A patent/HUE039167T2/hu unknown
- 2010-06-09 PL PL18158255T patent/PL3345903T3/pl unknown
- 2010-06-09 PT PT181582552T patent/PT3345903T/pt unknown
- 2010-06-09 ES ES10786195.7T patent/ES2575084T3/es active Active
- 2010-06-09 DK DK18158255T patent/DK3345903T3/da active
- 2010-06-09 PL PL15180863T patent/PL2975024T3/pl unknown
- 2010-06-09 DK DK10786195.7T patent/DK2441753T3/en active
- 2010-06-09 RU RU2011154150A patent/RU2585622C3/ru active Protection Beyond IP Right Term
- 2010-06-09 HU HUE10786195A patent/HUE028278T2/en unknown
- 2010-06-09 MX MX2011013306A patent/MX2011013306A/es active IP Right Grant
- 2010-06-09 EP EP19201621.0A patent/EP3613729A1/en active Pending
- 2010-06-09 MY MYPI2011004483A patent/MY159850A/en unknown
- 2010-06-09 EP EP15180863.1A patent/EP2975024B1/en active Active
- 2010-06-09 ES ES18158255T patent/ES2759510T3/es active Active
- 2010-06-09 CA CA2764653A patent/CA2764653C/en active Active
- 2010-06-09 MA MA34519A patent/MA33418B1/fr unknown
- 2010-06-09 ES ES15180863T patent/ES2668775T3/es active Active
- 2010-09-06 UA UAA201200237A patent/UA107796C2/ru unknown
- 2010-09-07 JP JP2010199935A patent/JP5628603B2/ja active Active
-
2011
- 2011-09-19 CR CR20110492A patent/CR20110492A/es unknown
- 2011-09-22 ZA ZA2011/06938A patent/ZA201106938B/en unknown
- 2011-09-30 CL CL2011002433A patent/CL2011002433A1/es unknown
- 2011-12-07 IL IL216817A patent/IL216817A/en active IP Right Grant
-
2012
- 2012-01-04 EC EC2012011573A patent/ECSP12011573A/es unknown
- 2012-01-06 CO CO12002119A patent/CO6430460A2/es active IP Right Grant
- 2012-06-29 HK HK12106400.7A patent/HK1165794A1/xx unknown
-
2015
- 2015-02-11 US US14/619,242 patent/US9440922B2/en active Active
-
2016
- 2016-06-02 CY CY20161100490T patent/CY1117752T1/el unknown
- 2016-06-06 HR HRP20160605TT patent/HRP20160605T1/hr unknown
- 2016-07-28 US US15/221,926 patent/US20160340308A1/en not_active Abandoned
-
2017
- 2017-06-01 FR FR17C1019C patent/FR17C1019I2/fr active Active
- 2017-06-02 LT LTPA2017017C patent/LTC2441753I2/lt unknown
- 2017-06-02 NL NL300876C patent/NL300876I2/nl unknown
- 2017-06-06 HU HUS1700026C patent/HUS1700026I1/hu unknown
- 2017-06-12 NO NO2017026C patent/NO2017026I1/no unknown
- 2017-06-14 LU LU00022C patent/LUC00022I2/fr unknown
- 2017-07-12 CY CY2017026C patent/CY2017026I1/el unknown
-
2018
- 2018-04-18 HR HRP20180615TT patent/HRP20180615T1/hr unknown
-
2019
- 2019-01-04 US US16/239,839 patent/US20200017442A1/en not_active Abandoned
- 2019-11-07 HR HRP20192022TT patent/HRP20192022T1/hr unknown
-
2020
- 2020-04-29 US US16/862,125 patent/US20220306578A1/en not_active Abandoned
-
2022
- 2022-07-08 US US17/860,589 patent/US20230142119A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR17C1019I2 (fr) | Compose tetracyclique | |
LTC2506716I2 (lt) | Nauji tricikliniai junginiai | |
SMT201600008B (it) | Composti di piridazinone | |
BR112012006859A2 (pt) | compostos | |
DK2427449T3 (da) | Vinylindazolylforbindelser | |
BRPI1013868A2 (pt) | composto diaciletilenodiamina | |
DK2376490T3 (da) | Imidazopyridinforbindelser | |
BRPI1008774A2 (pt) | espiroamida substituída | |
BRPI1013614A2 (pt) | compostos substituídos de espiro-amida | |
BRPI1005525A2 (pt) | compostos de azaazuleno | |
ECSP12011999A (es) | Derivados benzamida sustituidos | |
DK2397480T3 (da) | Diazepindionderivat | |
UY33156A (es) | Nuevos compuestos tienopirrol | |
DK2387580T3 (da) | Deoxyactagardinderivater | |
BRPI0923592A2 (pt) | composto | |
DOP2011000348A (es) | Construcciones casb7439 | |
BR112012009784A2 (pt) | composto benzazepínico | |
BR112012004643A2 (pt) | compostos antibióticos | |
BR112012006693A2 (pt) | combinação | |
BR112012006968A2 (pt) | combinação | |
BRPI1009199A2 (pt) | compostos de pirazinoisoquinolina | |
BRPI0913805A2 (pt) | composto | |
BRPI1014080A2 (pt) | Compostos substituidos de enaminocarbolina | |
BRPI0924006A2 (pt) | estrutura | |
FI20095580A (fi) | Kaivo |